Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.

Fernandes, B S; Steiner, J; Berk, M; Molendijk, M L; Gonzalez-Pinto, A; Turck, C W; Nardin, P; Gonçalves, C-A

Fernandes, B S; Steiner, J; Berk, M; Molendijk, M L; Gonzalez-Pinto, A; Turck, C W; Nardin, P; Gonçalves, C-A.

Afiliação

Fernandes BS; Laboratory of Calcium Binding Proteins in the Central Nervous System, Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Steiner J; Post-graduate Program in Biological Sciences: Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Berk M; Department of Psychiatry, University of Magdeburg, Magdeburg, Germany.
Molendijk ML; IMPACT Strategic Research Centre, Deakin University, School of Medicine, Barwon Health, Geelong, VIC, Australia.
Gonzalez-Pinto A; Florey Institute for Neuroscience and Mental Health, Department of Psychiatry and Orygen Research Centre, University of Melbourne, Parkville, VIC, Australia.
Turck CW; Department of Clinical Psychology, Institute of Psychology, Leiden University, Leiden, The Netherlands.
Nardin P; Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, The Netherlands.
Gonçalves CA; University of the Basque Country, Biomedical Research Center in Mental HealthNet (CIBERSAM), Department of Neurosciences, University of the Basque Country, Vitoria, Spain.

Mol Psychiatry ; 20(9): 1108-19, 2015 Sep.

Article em En | MEDLINE | ID: mdl-25266124

RESUMO

It has been postulated that schizophrenia (SZ) is related to a lower expression of brain-derived neurotrophic factor (BDNF). In the past few years, an increasing number of divergent clinical studies assessing BDNF in serum and plasma have been published. It is now possible to verify the relationship between BDNF levels and severity of symptoms in SZ as well as the effects of antipsychotic drugs on BDNF using meta-analysis. The aims of this study were to verify if peripheral BDNF is decreased in SZ, whether its levels are correlated with positive and negative symptomatology and if BDNF levels change after antipsychotic treatment. This report consists of two distinct meta-analyses of peripheral BDNF in SZ including a total of 41 studies and more than 7000 participants: (1) peripheral BDNF levels in serum and plasma were moderately reduced in SZ compared with controls. Notably, this decrease was accentuated with the disease duration. However, the extent of peripheral BDNF level decrease did not correlate with the severity of positive and negative symptoms. (2) In plasma, but not serum, peripheral BDNF levels are consistently increased after antipsychotic treatment irrespective of the patient's response to medication. In conclusion, there is compelling evidence that there are decreased levels of peripheral BDNF in SZ, in parallel to previously described reduced cerebral BDNF expression. It remains unclear whether these systemic changes are causally related to the development of SZ or if they are merely a pathologic epiphenomenon.

Assuntos

Antipsicóticos/uso terapêutico; Fator Neurotrófico Derivado do Encéfalo/sangue; Esquizofrenia/sangue; Esquizofrenia/tratamento farmacológico; Adulto; Biomarcadores/sangue; Estudos de Casos e Controles; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Adulto Jovem

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Fator Neurotrófico Derivado do Encéfalo Tipo de estudo: Observational_studies / Systematic_reviews Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google